China-focused venture capital firm Qiming Venture Partners has led a RMB200 million (US$29 million) series A round in Sino Biological Inc., a Beijing-based recombinant protein and antibody developer, according to a company announcement.
UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Read 2 Articles for Free with a Basic Account
Gain limited and restricted access to China Money Network.
Register Basic AccountSubscribe for an annual subscription!
Enjoy comprehensive and exclusive data you can't find elsewhere!
More Info
Already have an account or paid subscription? Log in
